Tag: NYSEMKT:TXMD

Finance

Drug Manufacturers Most Volatile: TherapeuticsMD Inc (NYSEMKT:TXMD), Pacira Pharmaceuticals (NASDAQ:PCRX), Heron Therapeutics Inc (NASDAQ:HRTX), Flexion Therapeutics (NASDAQ:FLXN)

TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company, will host a conference call and live audio webcast to disclose its financial results for the quarter ended March 31, 2014. The call and webcast will be held on Monday, May 5, 2014 at 4:30pm EDT and will be hosted by Robert Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright, Chief Financial Officer. TherapeuticsMD Inc (NYSEMKT:TXMD) stock … Continue reading Drug Manufacturers Most Volatile: TherapeuticsMD Inc (NYSEMKT:TXMD), Pacira Pharmaceuticals (NASDAQ:PCRX), Heron Therapeutics Inc (NASDAQ:HRTX), Flexion Therapeutics (NASDAQ:FLXN)

Mark DeFrance
FB Nasdaq FB Facebook
Finance

Drug Manufacturers Most Volatile: ITI Inc (NASDAQ:ITCI), TherapeuticsMD Inc (NYSEMKT:TXMD), KaloBios Pharmaceuticals (NASDAQ:KBIO), Auspex Pharmaceuticals Inc (NASDAQ:ASPX)

ITI Inc (NASDAQ:ITCI), a Company on the leading edge of transforming vaccines, announced the preliminary results of a Phase IB study of JRC-LAMP-vax™, a novel immunotherapy designed to treat individuals with allergy to Japanese red cedar (“JRC”). The Company is pleased to report that the Phase IB has met and maintained all primary safety and secondary immunological end points that were observed at the conclusion … Continue reading Drug Manufacturers Most Volatile: ITI Inc (NASDAQ:ITCI), TherapeuticsMD Inc (NYSEMKT:TXMD), KaloBios Pharmaceuticals (NASDAQ:KBIO), Auspex Pharmaceuticals Inc (NASDAQ:ASPX)

Jason Knox
Finance

Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 10.07% in last session and finished the day … Continue reading Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Colin Pettis